ClassID:

170435

G01N2333/5443 - CPC Classification

Classification description:

Assays involving biological materials from specific organisms or of a specific nature from animals; from humans; Assays involving cytokines; Interleukins [IL] IL-15

Recent Application in this class:
#1
20260049998
2026-02-19

METHODS OF DETECTING AND TREATING CEREBRAL ANEURYSMS

#2
20250383363
2025-12-18

NEUTRALIZATION ANTIBODY ASSAY METHOD

#3
20250347700
2025-11-13

METHODS OF DETECTING AND TREATING CEREBRAL ANEURYSMS

#4
20250314662
2025-10-09

NOVEL CYTOKINE-BASED THERAPIES AND METHODS

#5
20250224392
2025-07-10

METHOD FOR EVALUATING QUALITY OF INDUCEMENT INHIBITORY-T-CELL FORMULATION

#6
20240228569
2024-07-11

LONG-ACTING INTERLEUKIN-15 FUSION PROTEIN, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

#7
20240219385
2024-07-04

MOLECULAR SIGNATURES OF LONG-TERM COVID-19 AND TREATMENT THEREOF

#8
20240082307
2024-03-14

DIAGNOSTIC METHODS FOR T CELL THERAPY

#9
20230280356
2023-09-07

DRUG-SPECIFIC PHARMACOKINETIC ASSAY FOR IL-15 SUPERAGONIST

#10
20220341946
2022-10-27

BIOMARKERS FOR ASSESSING EXPLANT ORGAN VIABILITY

#11
20220220163
2022-07-14

RECOMBINANT DEAMIDATED GLIADIN POLYPEPTIDE ANTIGEN, RECOMBINANT ANTIGEN-EXPRESSING GENE, RECOMBINANT EXPRESSION VECTOR, AND PREPARATION METHOD AND APPLICATION THEREOF

#12
20220011313
2022-01-13

BIOMARKER PANELS FOR ON-TREATMENT PREDICTION OF RESPONSE TO IMMUNO-ONCOLOGY DRUGS

#13
20210082537
2021-03-18

Selective peptide antagonists

#14
20190315853
2019-10-17

Antibodies to IL-15 and uses thereof

#15
20180364229
2018-12-20

Biomarkers for assessing risk of transitioning to systemic lupus erythematosus classification and disease pathogenesis

#16
20180349550
2018-12-06

Selective peptide antagonists

#17
20180344767
2018-12-06

Diagnostic methods for T cell therapy

#18
20180209992
2018-07-26

Methods and compositions for treatment of autoimmune hepatitis

#19
20170276674
2017-09-28

Bioassay for the early detection of autoimmune diseases

#20
20170153251
2017-06-01

Methods of treatment of primary sclerosing cholangitis

#21
20170137511
2017-05-18

Antibodies to IL-15

#22
20160306918
2016-10-20

Methods of developing selective peptide antagonists

#23
20160231333
2016-08-11

Biomarkers for Tuberculosis

#24
20150219664
2015-08-06

Methods and compositions for diagnosis of inflammatory liver disease

#25
20150177250
2015-06-25

DETERMINATION OF EFFICIENT TIME(S) FOR CHEMOTHERAPY DELIVERY

#26
20150159221
2015-06-11

CANCER PROGNOSTIC ASSAYS

#27
20150017095
2015-01-15

PROSTAGLANDIN E2 DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF

#28
20120183568
2012-07-19

Bioassay for the early detection of autoimmune diseases

#29
20120058110
2012-03-08

Method for Predicting the Responsiveness to an Anti-TNF Alpha Antibody Treatment

#30
20100074900
2010-03-25

Prostaglandin E2 dual variable domain immunoglobulins and uses thereof

#31
20090068689
2009-03-12

Molecular phenotyping of severe asthma